Evotec and Yale University Form Open Innovation Alliance

Evotec and Yale University Form Open Innovation Alliance

HAMBURG, Germany, Jan. 9, 2013 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT)
(TecDAX) today announced that it has entered into a strategic partnership with
Yale University.

Under the agreement, Evotec and Yale intend to leverage first rate science
performed at Yale University together with Evotec´s drug discovery
infrastructure and expertise into highly innovative discovery approaches in
diseases of high unmet medical need. Initially, Evotec and Yale have defined a
wide range of scientific fields including metabolic diseases, CNS,
immunological diseases and cancer where they will jointly assess and
potentially pursue novel assays, screens and models but in particular
exploratory drug targets and compounds. The intention is to seamlessly
integrate Evotec's drug discovery infrastructure with highly innovative
biology at Yale to mature individual projects to a stage where they can be

Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: "We are very
excited about this open innovation alliance with Yale. There is a tremendous
wealth of scientific innovation at Yale that has the potential to be directly
translated into first- and best-in class drug candidates. Together we want to
significantly accelerate this process by removing technical bottlenecks and
focusing all efforts on bringing individual projects to highest industrial
standards in preparation for development and commercialisation partnerships
with Pharma companies."

"This agreement is a new collaboration model between academia and the
pharmaceutical industry. It essentially gives all faculties at Yale the
opportunity to directly translate new biological insights into top notch drug
discovery projects. Evotec is uniquely suited as a partner as they combine an
extremely broad drug discovery platform with fast processes and proven
commercialisation skills", said Dr Jon Soderstrom, Managing Director of Yale's
Office of Cooperative Research.

No financials were disclosed.


Founded in 1810, the Yale School of Medicine is a world-renowned centre for
biomedical research, education and advanced health care. Among its 27
departments are one of the nation's oldest schools of public health and the
internationally recognized Child Study Center, founded in 1911. Yale School of
Medicine consistently ranks among the handful of leading recipients of
research funding from the National Institutes of Health and other
organizations supporting the biomedical sciences. Its core faculty of more
than 1,100 physicians and scientists is well represented within the Institute
of Medicine and National Academy of Sciences and among investigators of the
Howard Hughes Medical Institute.


Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies. We operate worldwide providing the
highest quality stand-alone and integrated drug discovery solutions, covering
all activities from target-to-clinic. The Company has established a unique
position by assembling top-class scientific experts and integrating
state-of-the-art technologies as well as substantial experience and expertise
in key therapeutic areas including neuroscience, pain, metabolic diseases as
well as oncology and inflammation. Evotec has long-term discovery alliances
with partners including Bayer, Boehringer Ingelheim, CHDI, Genentech,
MedImmune/Astra Zeneca, Novartis and Ono Pharmaceutical. In addition, the
Company has existing development partnerships and product candidates both in
clinical and preclinical development. These include partnerships with
Boehringer Ingelheim, MedImmune and Andromeda (Teva) in the field of diabetes,
and with Roche in the field of Alzheimer's disease. For additional information
please go to www.evotec.com.

FORWARD LOOKING STATEMENTS — Information set forth in this press release
contains forward-looking statements, which involve a number of risks and
uncertainties. The forward-looking statements contained herein represent the
judgement of Evotec as of the date of this report. Such forward-looking
statements are neither promises nor guarantees, but are subject to a variety
of risks and uncertainties, many of which are beyond our control, and which
could cause actual results to differ materially from those contemplated in
these forward-looking statements. We expressly disclaim any obligation or
undertaking to release publicly any updates or revisions to any such
statements to reflect any change in our expectations or any change in events,
conditions or circumstances on which any such statement is based.

CONTACT: For further information, please contact:
         Dr Cord Dohrmann
         Chief Scientific Officer
         +49.(0)551.505 58 650
         +44.(0)40.560 81-333 Fax
         Evotec AG
         Manfred Eigen Campus
         Essener Bogen 7
         22419 Hamburg (Germany)
Press spacebar to pause and continue. Press esc to stop.